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Accumulating data generated from persons who naturally control HIV without the need
for antiretroviral treatment has led to significant insights into the possible mechanisms of
durable control of AIDS virus infection. At the center of this control is the HIV-specific CD8
T cell response, and the basis for this CD8-mediated control is gradually being revealed.
Genome wide association studies coupled with HLA sequence data implicate the nature
of the HLA-viral peptide interaction as the major genetic factor modulating durable control
of HIV, but host genetic factors account for only around 20% of the variability in control.
Other factors including specific functional characteristics of theTCR clonotypes generated
in vivo, targeting of vulnerable regions of the virus that lead to fitness impairing muta-
tions, immune exhaustion, and host restriction factors that limit HIV replication all have
been shown to additionally contribute to control. Moreover, emerging data indicate that
the CD8+T cell response may be critical for attempts to purge virus infected cells following
activation of the latent reservoir, and thus lessons learned from elite controllers (ECs) are
likely to impact the eradication agenda. On-going efforts are also needed to understand and
address the role of immune activation in disease progression, as it becomes increasingly
clear that durable immune control in ECs comes at a cost. Taken together, the research
achievements in the attempt to unlock the mechanisms behind natural control of HIV will
continue to be an important source of insights and ideas in the continuous search after an
effective HIV vaccine, and for the attempts to achieve a sterilizing or functional cure in HIV
positive patients with progressive infection.
Keywords: HIV, elite controllers, CD8+ T cells, immune activation, HIV vaccine
INTRODUCTION
As the vigorous research of elite controllers (ECs) continue to
unveil the various mechanisms behind durable and natural control
of HIV, a complex image that includes different factors is exposed.
Part of this milieu are components of the adaptive immune sys-
tem, mainly CD8+ and CD4+ T cells, innate immune responses
and cellular restriction factors, as well as specific characteristics
of the infecting virus itself (reviewed in Deeks and Walker, 2007).
CD8+ T cells were repeatedly found as one of the major contribu-
tors to natural control of HIV. Genome wide associations studies
consistently recognized the HLA peptide-binding grove (which
binds to the CD8+ T cell receptor, as well as to receptors on other
cells of the immune system) as one of the central genetic associa-
tions with HIV disease outcome (Fellay et al., 2007; International
HIV Controllers Study et al., 2010). Specific qualities of CD8+ T
cells from EC were recognized including their ability to inhibit
HIV replication ex vivo (Sáez-Cirión et al., 2007), to deliver cyto-
toxic granules to HIV infected target cells (Migueles et al., 2008),
to proliferate better (Migueles et al., 2002) and to exhibit multiple
effector functions at the same time (“polyfunctionality”) (Betts
et al., 2006; Ndhlovu et al., 2012a). It was also demonstrated that
CD8+ T cells from EC tend to be more cross-reactive (recognizing
virus variants and mutants) (Kosmrlj et al., 2010) and to prefer-
entially target more conserved and vulnerable parts of the HIV
virus (where the virus pays a higher fitness cost in order to escape
from the immune pressure exerted by cytotoxic T cells, CTL; Miura
et al., 2009).
It has been shown that CD4+ T cells from EC tend to be more
polyfunctional, produce more IL-2, and proliferate better (Dyer
et al., 2008; Ferre et al., 2010; Vingert et al., 2010). A few studies
have also demonstrated that CD4+ T cells from EC have reduced
permissiveness to HIV infection (Graf et al., 2011; Sáez-Cirión
et al., 2011). In that context, it was recently described that cell
restriction factors might contribute to the lesser vulnerability of
CD4+ T cells of EC to HIV infection and replication (Chen et al.,
2011). To that we should add the numerous reports that demon-
strated important contributions of the innate immune system to
elite control including natural killer (Lambotte et al., 2009; Vieil-
lard et al., 2010) and dendritic cells (Huang et al., 2010; Barblu
et al., 2012), as well as the contribution of special characteristics
of the infecting virus itself (Miura et al., 2010).
Despite the impressive achievements in the field of EC research,
our understanding of the mechanisms behind natural control
of HIV is still substantially lacking, and the unknown is likely
far greater than the known. In this review we examine these
achievements in light of their potential contribution to future
strategies for prevention and treatment, including vaccine design
and attempts for a functional or sterilizing cure. In this way we
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try to demonstrate that the research of EC goes beyond a pure
academic exercise. We emphasize lessons learned from the find-
ings achieved to date and their implications in planning the future
steps in the research of this unusual group of patients.
LESSON I – FROM IMMUNOLOGY OF ELITE CONTROLLERS TO
HIV VACCINE DESIGN
A major motivation behind the intensive study of EC is the inten-
tion to support the development of an effective HIV vaccine. If we
closely examine the insights achieved by the study of EC during the
past two decades we can see that several important immune corre-
lates were added to our toolkit to help evaluate vaccine candidates,
and some important principles learned can shed light on some of
the failures and successes in the field of HIV vaccine research.
In Merck’s phase IIb efficacy (STEP) trial, a replication-
defective adenovirus construct (Ad5) containing Gag, Pol, and Nef
genes was designed to induce T cell immune responses. The study
was prematurely halted as it failed to demonstrate protection from
acquisition of infection or to influence post infection viral load
(Buchbinder et al., 2008). Indeed, early analysis suggested that the
vaccine increased the risk of acquisition. A few principles learned
in EC can be demonstrated when examining this important clinical
trial. The failure of the vaccine was a surprise, mainly because of
positive indications of immunogenicity in earlier phases of the
vaccine or similar approaches in non-human primates (Shiver
et al., 2002; Priddy et al., 2008), and the understanding that T
cells play a central role in natural control of HIV, as demonstrated
earlier through CD8+ T cell depletion experiments in an animal
model of AIDS virus infection (Jin et al., 1999; Schmitz et al.,
1999), and by the strong association between certain HLA class I
alleles and disease outcome (Fellay et al., 2007; International HIV
Controllers Study et al., 2010). The major correlate of protection
used to evaluate cell-mediated immune responses in the STEP
study was interferon-γ enzyme-linked immunosorbent spot assay
(ELISPOT). Such responses were not expected to prevent infection
but rather to reduce steady state viremia, but despite induction
of these responses, there was no enhanced control of set point
viremia following infection (Buchbinder et al., 2008). Interferon-
γ-secreting HIV-specific T cells were detected by ELISPOT in the
majority of vaccinees, with similar proportion of responders both
in those that eventually became infected and those who remained
HIV negative (McElrath et al., 2008). Like this vaccine trial, there
is no correlation between cellular immune responses measured by
ELISPOT assays and clinical outcome (mainly viral load) in sev-
eral studies looking at EC, yet the clear association of certain HLA
alleles with control suggests that CD8+ T cell responses play a role
(Betts et al., 2001; Addo et al., 2003). The responses measured in
the vaccinees in the STEP trial were significantly narrower and
of lower magnitude in comparison to responses in EC (McElrath
et al., 2008) or in monkeys achieving virologic control after vacci-
nation with adenovirus vector-based SIV vaccine (Barouch et al.,
2012). But in that context it should be emphasized that the mag-
nitude and breadth of responses in ELISPOT assays were shown to
be a poor predictor of HIV control (Betts et al., 2001), and in fact,
it was demonstrated that CD8+ T cell responses in EC are usually
narrower and more focused on specific epitopes, especially in Gag
(Migueles et al., 2000). In the STEP trial, on the other hand, CD8+
T cell responses were more commonly directed toward Pol and
Nef than toward Gag (McElrath et al., 2008). Another major dif-
ference between vaccinees in the STEP trial and subjects naturally
controlling HIV lies in the way CD8+ T cells exhibit their effector
functions. While several studies have shown that an effective T cell
response in EC is usually polyfunctional (i.e., CD8+ T cells are able
to produce multiple cytokines simultaneously) (Betts et al., 2006),
in the STEP trial most vaccine-induced CD8+ T cells produced
interferon γ alone or in combination with TNFα only (McElrath
et al., 2008).
It’s also worth noticing that in the STEP trial only 41% of
the vaccinees developed HIV-specific CD4+ T cells that have the
potential to support and maintain long-term antiviral CD8+ T
cell memory, and only 31% mounted both CD4+ and CD8+ HIV-
specific T cells (McElrath et al., 2008). The ability to induce and
maintain effective memory is probably one of the central charac-
teristics expected from an effective vaccine. This principle is also
important for natural control of HIV, and favorable characteris-
tics of T cell memory have been demonstrated in EC (Ndhlovu
et al., 2012b). It has been shown that EC show both effective and
functional memory responses, and that central-memory (TCM)
and effector memory (TEM) CD4+ T cells in EC are less suscep-
tible to apoptosis and persist longer after repeated stimulations
as compared to aviremic HIV infected subjects treated with anti-
retroviral treatment (van Grevenynghe et al., 2008). Furthermore,
it has been recently shown that TEM are the most effective CD8+ T
cell sub-population at suppressing viral replication in EC (Buck-
heit et al., 2012). In contrast to states of high antigen load (as
is expected in uncontrolled HIV infection), it has been shown
that memory cells in states of lower antigen load are able to per-
sist longer, show lower degree of senescence, higher proliferative
capacity, and therefore better functional properties (West et al.,
2011). Therefore, EC are likely to be an important indicator for
the desired way of maintaining memory CD4+ and CD8+ T cells.
The relevance of these findings to vaccine research was demon-
strated in a recent proof-of-concept study in which researchers
have used an SIV protein-encoding vector based on rhesus
cytomegalovirus (Hansen et al., 2009, 2011). By using a persis-
tent vector that leads to a controlled, continuous level of anti-
gen expression, robust SIV-specific CD4+ and CD8+ TEM cell
responses were primed and maintained. This approach led to
impressive protection from acquisition (significantly higher num-
ber of challenges needed to cause infection), and importantly to
control of post infection viremia in the monkeys, a state that may
be similar to elite control or functional cure in humans. The effec-
tiveness of this new approach (in NHP at this stage) renders great
hope in the field of HIV vaccine research (Walker et al., 2011). In
contrast to older strategies (as that used in the STEP trial) when a
non-persistent vector is used and TCM is the predominant mem-
ory population elicited, this new strategy leads to development
and maintenance of a potent TEM population, thus a faster and
more effective systemic and mucosal T cell responses develop. Our
own data show that the HIV-specific TEM population in EC pre-
dominates and is less prone to apoptosis/deletion as compared to
CP (unpublished data).
Although extrapolation of immune correlates of protection in
chronic HIV infection to predict protection in vaccine trials might
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be misleading, the field of HIV vaccine development desperately
needs better-defined immune measures that are able to predict
vaccine efficacy. The study of ECs, by detailed dissection of the
components that lead to natural control, added several such cor-
relates, and it would be reasonable to assume that some of them
would be considered in future clinical trials. This includes the abil-
ity of CD8+ T cells to directly inhibit HIV replication ex vivo, their
ability to proliferate, and to exhibit polyfunctional effector profile,
as well as the composition of the memory subsets induced.
LESSON II – ELITE CONTROLLERS, FUNCTIONAL CURE, AND
HIV ERADICATION
The most prominent characteristic of EC, complete suppression of
the viremia to undetectable levels, can be easily achieved by com-
bination antiretroviral treatment. But some unique and desirable
features in EC are absent in non-controllers treated with HAART.
Obviously, in contrast to EC, the suppression of the viremia in
HAART treated patients requires lifelong medications that are
both expensive, and carry the risk for toxicity. Until recently, treat-
ment interruptions universally resulted in viral rebound, and lack
of adherence carries the risk for emergence of resistant virus that
further complicates the therapeutic regimen. Life expectancy has
never been compared between a cohort of untreated EC and non-
controllers treated with antiretrovirals, but it has been demon-
strated that subjects naturally controlling HIV have smaller HIV
reservoirs compared to progressors treated with HAART (Graf
et al., 2011; Buzon et al., 2012), and that recovering virus from EC
seems to be more difficult as compared to HAART treated patients
(Julg et al., 2010). Therefore, it appears as EC are an excellent
model of functional cure, a state in which the virus is maximally
suppressed, although not cleared, and the integrity of the immune
system is maintained relatively intact by the patient’s own defense
mechanisms and without the need for life long medications.
Elite controllers inspired researchers to try to induce a similar
state of control in infected subjects that do not control the infec-
tion spontaneously, and research is on its way in that direction.
The most encouraging attempt in that direction was achieved in
patients treated with antiretrovirals shortly after infection. In a
recent report from France 12 patients out of 75 (16%) who started
combination antiretroviral treatment within 10 weeks after HIV
infection kept their viral load<50 copies/ml for more than 6 years
after discontinuing the antiretroviral treatment (Hocqueloux et al.,
2010; Bacchus et al., 2012). The prevalence of elite control in that
intervention group was more than 30-fold higher compared to
a cohort of non-selected HIV infected individuals (in which the
frequency of EC is usually <0.5%). In contrast to EC, the acutely
treated cohort was not enriched with protective HLA alleles like
HLA-B57 or B27, but rather with HLA-B35, which is associated
with rapid disease progression (Carrington et al., 1999), but the
reservoir (HIV DNA) in treated patients becoming controllers had
similar characteristics compared to EC in terms of magnitude and
distribution.
The principle of early treatment was also employed in an
interesting case of congenital HIV infection, in which immedi-
ate treatment after birth with a full dose antiretroviral regimen
led to sustained suppression of viral replication despite prolonged
treatment discontinuation (Persaud et al., 2013). These cases of
early treatment differ in the approach taken compared to other
early intervention studies in both children and adults, in which
pulse therapy was largely used, and duration of treatment was
much briefer in these patients who did not control after treatment
discontinuation (Kaufmann et al., 2004; Fortuny et al., 2011).
It would be important to reveal the mechanisms involved
in inducing a state of viral control in patients not harboring
protective HLA alleles treated early during the course of acute
infection. In a study by our group interesting insights came up
from close examination of the transition from acute to chronic
controlled infection (Miura et al., 2010). Looking at a cohort of
acutely infected subjects not enriched with protective HLA alle-
les that eventually became HIV controllers significantly higher
prevalence of drug resistance or CTL escape mutations associated
with impaired viral fitness was found in controllers compared to
non-controllers. This work implies that the characteristics of the
transmitted virus itself can dictate the fate of the infection natural
course. Further examination of the mechanisms leading to elite
control after acute infection would broaden our understanding of
the way patients become ECs and ways to intervene and induce
such a state.
Lessons learned from EC are also influencing cure strategies
involving gene therapy. The class I HLA alleles B57 and B27 are
the most recognized genetic elements associated with HIV con-
trol, and recently several studies have demonstrated that HLA-B27
and B57 restricted TCR clonotypes from EC have superior ability
to suppress HIV-1 replication in vitro (Chen et al., 2012), greater
cross-reactivity to epitope variants (Chen et al., 2012; Ladell et al.,
2013) and enhanced loading and delivery of perforin in com-
parison to HLA-B27 and B57 restricted TCR clonotypes form
non-controllers (Chen et al., 2012). Researchers are now exam-
ining the possibility to modulate the TCR repertoire of patients
not carrying protective HLAs, or having immunodominant non-
effective TCR clonotypes by TCR gene transfer (Varela-Rohena
et al., 2008; Barsov et al., 2011; Hofmann et al., 2011). By doing
that, the purpose is to provide CD8+ T cells clones with all the
superior characteristics recognized in patients controlling HIV.
This idea was proven promising in an animal model at this stage,
but active research is still on its way. While adoptive transfer of
ex vivo-expanded autologous or allogeneic HIV-1-specific CTLs
into HIV-1-infected individuals had minimal effect on HIV-1 viral
load (Lieberman et al., 1997; Tan et al., 1999; Bolton et al., 2010),
as the immunodominant CTL clones in patients with progressive
infection are usually exhausted and more susceptible to apopto-
sis, transduction of primary CD8+ T cells with TCR genes from
Gag specific clone harboring potent inhibition capacity led to an
impressive in vivo inhibition of HIV in a mouse model (Joseph
et al., 2008). This exciting idea is awaiting further evaluation in
NHP models and in humans.
The use of genetic engineering in the field of HIV cure research
has received inspiration from some other findings in EC and by
examining mechanisms involved in viral entry. It is well established
that a 32 base pair deletion in the HIV co-receptor C–C chemokine
receptor 5 (CCR5) gene confers profound resistance to infection
by R5 tropic viruses, and indeed, it has been shown that ∆32 het-
erozygosity is more prevalent among EC or is associated with lower
viral load (Magierowska et al., 1999; International HIV Controllers
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Study et al., 2010). This important notion not only served the field
of antiretroviral therapy development (Gulick et al., 2008), lead-
ing to a pharmacologic intervention to block this receptor, but
was also employed in an outstanding key work in which HIV cure
was achieved by allogeneic bone marrow transplantation in HIV
infected patient with acute leukemia. This patient, known as the
“Berlin patient,”received hematopoietic stem cell (HSC) graft from
a donor homozygous for ∆32 (Hütter et al., 2009) and eventually
achieved sustained undetectable viremia despite discontinuation
of antiretroviral treatment for more than 3 years (Allers et al.,
2011). The same idea is being examined in several studies in which
researchers are trying to artificially induce a deletion in the co-
receptor by genetic engineering using zinc finger nucleases (ZFN)
(Holt et al., 2010). Doing so, researchers were able to disrupt the
CCR5 gene in human HSCs and to engraft them into immunode-
ficient mice. Mice transplanted with ZFN-modified HSC, and later
infected with HIV, underwent rapid selection for CCR5-negative
cells, and showed significantly lower HIV-1 levels in both periph-
eral blood and gut mucosa, as well as restoration of normal levels
of human CD4+ T cell levels throughout their lymphoid tissues.
Examination of this concept in humans is currently underway
(Tebas et al., 2011; Maier et al., 2013).
Additional work is now taking place examining ways to pro-
mote HIV cure, and an international consortium was established
specifically for that purpose (International AIDS Society Scientific
Working Group on HIV Cure et al., 2012). No doubt that insights
learned from the immunology and virology of EC will continue to
provide major support to those efforts. The ideas under examina-
tion that are inspired by EC research include the efforts to induce
strong and effective T cell responses by vaccination [an area that
experienced failures and disappointments (Autran et al., 2008),
but received some positive results recently utilizing dendritic cells
based therapeutic vaccine (García et al., 2013)]. Efforts are also
concentrated on attempts to attack and reduce the viral reservoir,
to eliminate latently infected cells by activation (using IL-7, histone
deacetylase inhibitors, prostratin, and others) in conjunction with
induction of effective cytotoxic responses, in addition to the pre-
viously mentioned ideas. The possibility of identifying a way for
patients to stop antiretroviral treatment and acquire a phenotype
similar to ECs is a great challenge that might have significant clini-
cal, epidemiological, and financial implications, but is not without
risks due to persistent immune activation. Therefore, scientists
and clinicians from different disciplines must continue and work
together to take this important goal forward.
LESSON III – ELITE, BUT IMPERFECT CONTROL – THE ROLE
OF IMMUNE ACTIVATION
Life expectancy in HIV infected individuals has improved dra-
matically since the introduction of highly active antiretroviral
treatment (Bor et al., 2013), but studies show that it is still
compromised compared to matched uninfected controls (Lohse
et al., 2007; Nakagawa et al., 2012). Non-AIDS events among HIV
infected individuals (including malignancies, cardiovascular, liver,
renal, bone disease, and others) are increasingly recognized since
HIV became a chronic condition (Guaraldi et al., 2011), and it
is clear now that undetectable plasma viremia is not sufficient to
prevent such complications. Excess morbidity and mortality in
treatment-suppressed HIV infected individuals were attributed to
multiple etiologies including toxicity of the antiretroviral treat-
ment, higher rates of co-infections (like HCV and HBV), life style
and risk behavior (smoking, drug, and alcohol use), and lower
socioeconomic status. But even after adjustment for those factors,
higher rates of comorbidities were found compared to uninfected
controls, and there is a broad recognition today that a major
cause of that is the deleterious effect of the continuous inflamma-
tion and immune activation described in these patients. Increased
levels of T cell activation (CD38 and HLA-DR), innate immu-
nity activation (CD16 and IL-6 produced by monocytes, IFN-α
by dendritic cells, and others) as well as markers of microbial
translocation (LPS and other microbial products) and impaired
coagulation (d-dimer) were found in chronically infected patients,
both treated and untreated, and were associated with increased
morbidity (Hsue et al., 2012; Marks et al., 2013; Morse et al., 2013)
and mortality (Cozzi-Lepri et al., 2011; Achhra et al., 2012).
In that context, EC serve as an important model to study
immune activation. By eliminating confounding factors present
in other patient populations (the drug toxicity in HAART treated
patients with undetectable viral load, or the influence of the on-
going viremia in chronic untreated patients) researchers were able
to get a better understanding of the pathogenesis and harm caused
by immune activation.
Elevated markers of immune activation and bacterial translo-
cation were found in EC as compared to HAART treated patients
(Hunt et al., 2008, 2011), and these abnormalities were associated
with lower CD4+ cell counts. Excess morbidity from non-AIDS
conditions was also found in EC compared to HAART treated
patients with undetectable viral load. In a recent work, the preva-
lence of coronary atherosclerosis (estimated by coronary CT) was
unexpectedly higher among EC with sustained viral suppression
(no history of viral “blips”) compared to HIV negative individual
or HIV infected patients treated with antiretroviral and main-
taining undetectable viral load (Pereyra et al., 2012). The higher
prevalence of coronary disease was associated with elevated mark-
ers of innate immune activation (sCD163, a marker of monocyte
activation) as well as markers of CD8+ T cells activation (CD38
and HLA-DR). Increased levels of carotid artery intima-media
thickness (another manifestation of accelerated atherosclerosis)
was also found in EC, and was associated with C reactive pro-
tein, a marker of inflammation (Hsue et al., 2009). It has been
shown that EC and viremic controllers (those controlling the
virus to levels below 2000 copies/ml) have high level of collagen
depositions and fibrosis in the gut associated lymphoid tissues,
a feature of immune activation and end-organ damage (Sanchez
et al., 2013). Surprisingly, the degree of collagen deposition was
higher in EC compared to HAART treated patients, uninfected
individuals or to that found in the “Berlin patient,” known to be
cured of HIV. Some other manifestations of immune dysfunctions
were demonstrated in EC. A non-negligible portion (about 10%)
of EC progress to AIDS or show progressive loss of their CD4
despite the undetectable viremia (Hunt et al., 2008). Furthermore,
in studies in which EC initiated HAART for various clinical indi-
cations, CD4+ T cell gain was inferior compared to that achieved
in non-controllers (Okulicz et al., 2010). These findings imply that
despite the impressive control of the plasma viremia in EC, still a
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significant level of immune activation/dysfunction is present and
is associated with various forms of end-organ damage, and might
compromise long-term prognosis.
In addition to the observations of increased immune activation,
the study of EC helped to explore the various etiologies contribut-
ing to its pathogenesis. Like in studies looking at HAART treated
patients with undetectable plasma viremia (Buzón et al., 2010),
data collected in EC showed that continuous viral replication exists
despite the undetectable plasma viremia by standard assays, and
it might play a major role in the pathogenesis of chronic immune
activation. Utilizing ultrasensitive assays it has been shown that
low-level plasma viremia is common in EC, and indeed, 98% of EC
had detectable low-level viremia at some point during prolonged
follow-up (Hatano et al., 2009). Median plasma viral load of 2
copies/ml was found in EC (Pereyra et al., 2009), a level higher than
that usually documented in HAART suppressed patients (Hatano
et al., 2009). Cell associated RNA and persistent cell integrated
DNA were also evident in EC, and replication competent virus
was isolated from these patients (Blankson et al., 2007). Further-
more, some studies have demonstrated that viral evolution occurs
in EC, a clear evidence that on-going replication is taking place
(O’Connell et al., 2010). These findings imply that the immune
system of EC is continuously exposed to low-level release of viral
products, which might trigger the state of continuous immune
activation and chronic inflammation.
Other factors involved in the pathogenesis of immune activa-
tion were described in EC. It is well established that HIV infection
is associated with disruption of the gut mucosal barrier and per-
sistent translocation of bacterial products, which in turn lead to
systemic immune activation (Brenchley et al., 2006; Wallet et al.,
2010). Like in other cohorts of chronically HIV infected individ-
uals, increased markers of microbial translocation were found in
EC (Hunt et al., 2008). In a study that compared EC, HIV negative
individuals, and untreated HIV infected patients, LPS levels were
significantly higher in EC compared to HIV negative controls, and
similar to the levels in untreated patients. These findings were
associated with higher levels of CD8+ T cells activation (Hunt
et al., 2008). Such abnormalities might explain the higher levels
of fibrosis in the gut associated lymphoid tissue of EC, mentioned
before (Sanchez et al., 2013).
To that we should add other conditions that might play a role
in the pathogenesis of immune activation in EC, including co-
infections with other persistent pathogens like HBV and HCV, the
highly effective immune responses in EC that play an important
role in controlling the infection but at the same time might facil-
itate the state of inflammation and immune activation, and other
etiologies yet to be defined.
Vigorous research is taking place these days exploring ways
to minimize or prevent immune activation and its harmful
consequences. The ideas being examined include attempts to
eliminate residual viral replication by treatment intensification
with antiretrovirals (Buzón et al., 2010; Massanella et al., 2013),
interventions to improve gastrointestinal tract integrity (Klatt
et al., 2013) and to eliminate other persistent co-infections,
treatment with non-specific inhibitors of chronic inflammation
like statins, anti-inflammatory agents, anti-cytokine and anti-
chemokine agents, immunosuppression, and others (Rajasuriar
et al., 2013). The study of EC gives important support in that
direction as well, taking advantage of the unique properties of this
group of patients. In a recent report, patients naturally control-
ling HIV (both viremic and ECs) were thoroughly examined after
24 weeks of prospective treatment with combination of three anti-
retroviral drugs (Hatano et al., 2013). This intervention led to a
significant decrease in plasma RNA by ultrasensitive assay, decrease
in markers of T cell activation in blood and the gut, and decrease
in the percentage of PD-1+ CD4+ and CD8+ T cells. This work
demonstrates that significant reduction in immune activation in
controllers is possible by eliminating residual viral replication. It
would be interesting to examine the influence of other treatment
modalities in this group of patients and especially in patients that
effectively control HIV but still progress to AIDS.
CONCLUDING REMARKS
The phenomenon of natural control of HIV inspired many
researchers who take part in the efforts to develop new preven-
tive and therapeutic modalities for HIV. Exploring the impressive
balance between the host and the virus, several new ideas came out
that might serve the field of development and evaluation of new
vaccine candidates and other modalities of immunotherapy, the
field of HIV treatment, and the efforts to eradicate the infection
and to lead to HIV cure. The study of EC taught us few lessons
about the complex network of components that contribute to the
natural control of the virus and the different arms of the immune
system involved. The markers of control identified in EC might
serve as an important and more accurate correlates of protection
in studies of vaccine candidates, and effective immune responses
might be transferred by genetic engineering into subjects not nat-
urally controlling HIV. The study of EC also provided new ideas
and tools to the field of HIV cure research and to the attempts
to achieve HIV eradication, and different ways to induce a state
similar to EC are still being examined. The damage caused by
chronic inflammation and immune activation is increasingly rec-
ognized as an important element compromising the prognosis of
HIV infected individuals, and a model of HIV infected patients
with undetectable viremia and no exposure to antiretroviral med-
ications is an important tool to study the etiology and influence
of these deleterious processes.
As the mechanisms behind natural control of HIV are only par-
tially understood, much effort is still needed to be carried out, and
research must continue in new directions and toward new ideas.
No doubt the findings revealed by these efforts will have a major
impact on the way we treat and prevent HIV in the future.
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